August 2012
-
According to Tiziana Life Sciences, the FDA has approved the company’s IND for a Phase 2a trial of intranasal foralumab in patients with multiple system atrophy (MSA). The company is currently developing intranasal foralumab for the… Read more . . .
-
MannKind Corporation announced a strategic financing agreement with Blackstone that will provide the company with a $75 million loan initially, with a total potential of up to $500 million. MannKind said that the agreement was made in… Read more . . .
-
Ethris has announced the initiation of a Phase 2a trial of its intranasal ETH47 mRNA-based antiviral in asthma patients. The Phase 2a study is expected to enroll 50 adult patients who will receive either ETH47 or… Read more . . .
-
Alveolus Bio, which is developing inhaled therapies for the treatment of respiratory diseases, announced that Indian API manufacturer and CDMO Shilpa Medicare Limited has led a strategic financing round that will fund Phase 2 development… Read more . . .
-
AeroRx Therapeutics announced that a Phase 2a trial of its AERO-007 indacaterol / glycopyrrolate inhalation solution demonstrated statistically significant improvements FEV1 versus placebo for both doses studied. According to the company, the inhalation solution is… Read more . . .
-
Rocket Science Health, which recently partnered with Kindeva on development of its nasal delivery device, announced that the US Patent and Trademark Office (USPTO) has issued the company US Patent No. 12,343,489, titled, “Intranasal and… Read more . . .
-
GSK has announced that it will pay $500 million to Hengrui Pharma up front for the rights to Hengrui’s HRS-9821, an inhaled dry powder PDE3/4 inhibitor for the treatment of COPD, plus options to license… Read more . . .
-
According to AstraZeneca, the EMA’s the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion regarding the company’s LGWP version of Trixeo (Breztri) Aerosphere budesonide / glycopyrronium / formoterol MDI, which uses Honeywell’s Solstice… Read more . . .
-
Avalyn Pharma announced that it has closed a $100 million Series D financing, with proceeds intended to support continued development of its inhaled drugs for the treatment of pulmonary fibrosis, including AP01 pirfenidone, AP02 nintedanib,… Read more . . .
-
HCmed Innovations announced that the FDA has granted 510(k) clearance to the company’s AdheResp connected breath-actuated mesh nebulizer, which delivers aerosol during inhalation only. According to the company, AdheResp is the first nebulizer of its… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.